Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. - Wikidata - awgldk - TriplyDB

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.

http://www.wikidata.org/entity/Q34559914

about

Cholinesterase inhibitors for Alzheimer's disease Rivastigmine for Alzheimer's disease Rivastigmine for Alzheimer's disease Rivastigmine for Alzheimer's disease Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease.Does analysis using "last observation carried forward" introduce bias in dementia research?Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.Predictors of long-term cognitive outcome in Alzheimer's disease Broader considerations of higher doses of donepezil in the treatment of mild, moderate, and severe Alzheimer's disease.Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease.Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil.Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice.Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease.A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Progress update: Pharmacological treatment of Alzheimer's disease.Dementia of the Alzheimer type.Current concepts in Alzheimer's disease: a multidisciplinary review.Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.Donepezil in the treatment of patients with Alzheimer's disease.Behavioral Changes and Hippocampus Glucose Metabolism in APP/PS1 Transgenic Mice via Electro-acupuncture at Governor Vessel Acupoints Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias.Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.Caprospinol: discovery of a steroid drug candidate to treat Alzheimer's disease based on 22R-hydroxycholesterol structure and properties.Treatment of dementia with Lewy bodies and Parkinson's disease dementia.Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.

P2860

Q22252975-7F5D0901-4AF8-4726-B62D-30855CD1BC57 Q24186551-529FD5A3-4FDA-4FD6-AC3F-14EC449C5F23 Q24187067-7BC50821-731D-4019-A1EC-9AAD58710C0D Q24241686-FBDB6C76-069D-4104-B550-BF22C00D2B54 Q33715239-18218CF9-82F4-41C5-AF3C-FEB2C7E3B24F Q34222721-E1EA0FEC-4C74-43E4-B436-9E7CEEB78C42 Q34632737-F3BFDBC3-D233-4143-8859-91A20D8E4CAD Q34846882-9828C8F0-CD12-44C4-A27F-327134F00613 Q34965949-50FA500D-5EFF-4E57-93F7-E7653978F2B4 Q35327053-81A99036-8AE7-4D36-A021-BE23F0DF55B8 Q35579243-4DBA53DE-F7DF-4514-BC78-5280B5EF6158 Q35606762-22AE32C1-803F-4ACC-A910-E5BD465D38EF Q35626834-BAD6D6CD-FE9F-4E53-85DB-AE6E1C5A5CD2 Q35631407-EACE7ADD-F31F-4421-97A0-3E792ADEA8D5 Q35987359-54EDDFCE-0BB4-4B22-BA77-49ACF2ACB74F Q36226630-6EFA4685-2F2F-4450-9395-5CFED959146B Q36475090-C64B21FF-1831-4AB1-AE44-1BEDDEF717C6 Q36500123-A4F75F1B-35B5-44A6-86D0-54D9D1CDC2D0 Q36538811-1FB1055E-BA5A-4FD6-8D0B-D53362456532 Q36632771-552883B4-6D3A-445B-A35E-9DB7CA90C626 Q36663678-EA0F95FF-1729-4336-B0C3-5B88F75943EA Q36897422-54C9A3E6-3FA8-43F8-A1A6-6D8339C17495 Q36978027-74ECA8ED-F945-4AF6-9EF8-991E060D4397 Q37070395-0B22804C-E14C-4D4F-9B9B-054DCE12BBDC Q37129735-3F7778BB-8BC2-47AB-831F-766D8CA4C42F Q37219298-276461E6-0EC7-4042-9A5C-673096DEEBA8 Q37360292-E03E1A20-28CA-4415-B380-C484BA9DF817 Q37396299-19C3ECC7-108B-4E2F-80E4-9241A9211969 Q37464161-77AE2275-A466-49C1-A1FB-8C373B38F9BA Q37601981-F0CCE1B1-149E-4F09-B406-177387B9456C Q37693772-270062E1-0A4C-4F7C-B1A8-BCC5C5140D0F Q37834619-246309E6-DC4A-4A02-897A-41AAB5B66697 Q37842435-A1BA0AEE-EB7A-4037-81BA-868D7651C60D Q37882023-99237AB3-A9D9-493B-8CFD-A69B2A3F2891 Q37942219-539389F8-49C0-4D9E-B4D0-88760948D389 Q38225721-078B4E5B-F679-4A8B-8195-B39997448B27 Q38247181-7657FAE4-E793-4B57-938C-8C088E3CBFC3 Q38661735-9BA4B829-50AA-4612-B1B7-3402D7EF4A8D Q38672790-7AEB6EF3-2C72-40BF-AEDD-B920FDC79167 Q39837265-A61DCF76-6E9D-4DB3-A6D7-B0DEBC840A38

P2860

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.

http://www.wikidata.org/entity/Q34559914

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Rivastigmine and donepezil tre ...... disease over a 2-year period.

@ast

Rivastigmine and donepezil tre ...... disease over a 2-year period.

@en

Rivastigmine and donepezil tre ...... disease over a 2-year period.

@nl

type

label

Rivastigmine and donepezil tre ...... disease over a 2-year period.

@ast

Rivastigmine and donepezil tre ...... disease over a 2-year period.

@en

Rivastigmine and donepezil tre ...... disease over a 2-year period.

@nl

prefLabel

Rivastigmine and donepezil tre ...... disease over a 2-year period.

@ast

Rivastigmine and donepezil tre ...... disease over a 2-year period.

@en

Rivastigmine and donepezil tre ...... disease over a 2-year period.

@nl

P1433

Q34559914-A3DEA2F3-CAF2-4BE2-93B8-DAEB9A5FEE51

P1476

Q34559914-22E835AC-1FA8-4D0D-94F7-ABAD803B2ECD

P2093

Q34559914-250FE140-AC2E-40BD-B7DF-39EE2D78C6B4

Q34559914-2C352C0D-A468-4745-BC7C-30A16FA618CD

Q34559914-580A7F3C-BCD5-47EF-9F08-B258E3FF9315

Q34559914-58646B10-D395-41DE-93B6-5614E4F1D3B0

Q34559914-91D71276-B8BC-4475-95D5-5603D7009A28

Q34559914-96E0C519-F93D-41B0-8283-2AD5A132F90F

Q34559914-BCAFF88E-E463-4C74-80D7-B9DFE231B921

Q34559914-C9344E73-DE8D-43B9-ADA4-CB6F71DD1CF6

P304

Q34559914-1CDE9225-6309-4353-B5CB-4354046F62D9

P31

Q34559914-6F8C2CF1-A5C5-4DFE-8213-A2E6E4F516E8

P356

Q34559914-98192C9E-227C-4B70-8B67-3C499CD7E5B4

P407

Q34559914-73A35C39-8617-403D-BFE2-C6F4BD9EF5DE

P433

Q34559914-5F2C8711-2E7C-418A-849A-1C14F47D49A8

P478

Q34559914-204737C6-7406-426A-937A-0701024BC263

P577

Q34559914-7C07754B-9393-4D5F-AD6F-E2A4B167A55F

P698

Q34559914-57FF3C05-FBEE-4692-8021-9BE108C1C9DB

P921

Q34559914-90647701-3DED-47D4-A51A-D3F6D289E441

P356

030079905X56565

P1433

Current Medical Research and Opinion

P1476

Rivastigmine and donepezil tre ...... disease over a 2-year period.

@en

P2093

Giuseppe Gambina

http://www.w3.org/2001/XMLSchema#string

Günter Rapatz

http://www.w3.org/2001/XMLSchema#string

Howard Bergman

http://www.w3.org/2001/XMLSchema#string

Jacques Touchon

http://www.w3.org/2001/XMLSchema#string

Jennifer Nagel

http://www.w3.org/2001/XMLSchema#string

Roger Bullock

http://www.w3.org/2001/XMLSchema#string

Roger Lane

http://www.w3.org/2001/XMLSchema#string

Yunsheng He

http://www.w3.org/2001/XMLSchema#string

P304

1317-1327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1185/030079905X56565

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16083542

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease